返回
Passage Bio Inc（PASG）價格
PASG 股價走勢圖
PASG 收益
Passage Bio Inc
$12.87
-9.87%
$-1.41
收盤價：Jan 16, 16:00:00 GMT-5
$12.87
0%
$0
盤後：Jan 16, 20:00:00 GMT-5
關鍵數據
前收市價
$14.28
開盤價
$14.32
當日範圍
$12.5 - $14.8
52週區間
$5.12 - $20
交易量
40.3K
平均成交量
58.4K
每股盈餘 (TTM)
-14.47
股息收益率
--
市值
$40.9M
什麼是 PASG？
Passage Bio, Inc. operates as a genetic medicines company. The company is headquartered in Philadelphia, Pennsylvania and currently employs 60 full-time employees. The company went IPO on 2020-02-28. Its lead clinical product candidate, PBFT02, seeks to elevate progranulin levels to enhance lysosomal function and slow disease progression across a variety of neurodegenerative diseases. PBFT02 utilizes an adeno-associated virus serotype 1, or AAV1, capsid to deliver a functional granulin gene, encoding progranulin (PGRN), to the brain via intra cisterna magna (ICM) administration. Its development programs consist of PBFT02 for the treatment of FTD-GRN, PBFT02 for the treatment of FTD-C9orf72 and amyotrophic lateral sclerosis, and PBFT02 for the treatment of Alzheimer’s disease. Its clinical product candidates include PBGM01, PBKR03 and PBML04. The company has one unnamed preclinical research program that explores multiple potential treatment targets for Huntington's disease.